Anal Fistula Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major anal fistula markets are expected to exhibit a CAGR of 3.4% during 2024-2034.
The anal fistula market has been comprehensively analyzed in IMARC's new report titled "Anal Fistula Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anal fistula is an abnormal tunnel or tract that forms between the anal canal or rectum and the skin surrounding the anus. It can vary in complexity, with some being straightforward and others more intricate with multiple tracts. The common symptoms associated with the ailment include persistent or recurrent pain around the anus, particularly during bowel movements, discharge of pus or blood from the opening near the anus, swelling or a lump near the anal region, itching or irritation around the anal area, and occasionally, fever. The specific indications experienced may vary depending on the characteristics of the fistula, and some patients may have minimal or no signs at all. Diagnosing an anal fistula typically involves a thorough examination by a healthcare professional, such as a colorectal surgeon. The diagnosis is made through a combination of physical exam and medical history review. The healthcare provider may visually inspect the anal area, looking for signs of an opening or discharge. Additional diagnostic tests, including endoanal ultrasound or magnetic resonance imaging (MRI), are also performed to visualize the fistula tract, determine its characteristics, and evaluate any underlying causes.
The escalating incidences of inflammation in the digestive tract that can weaken the tissues, impair healing, and create abnormal connections or tunnels between the anal canal or rectum and the surrounding skin, are primarily driving the anal fistula market. In addition to this, the rising cases of injuries or trauma to the anal or rectal area, such as during childbirth and surgery, infections in the perianal region, previous surgical procedures involving the anus or rectum, anal abscesses, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of fistula plugs made of biological or synthetic materials, since they offer a less invasive option with the potential for quicker healing and reduced recurrence rates, is further bolstering the market growth. Apart from this, the inflating application of intersphincteric fistula tract (LIFT) procedure that involves identifying and ligating the internal opening of the fistula and removing the diseased tissue is also acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive techniques, such as video-assisted anal fistula treatment (VAAFT) and endoanal ultrasound-guided therapy (EUA), which allow for precise identification of the fistula tract and targeted intervention while minimizing tissue damage, is expected to drive the anal fistula market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the anal fistula market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for anal fistula and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anal fistula market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the anal fistula market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the anal fistula market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current anal fistula marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the anal fistula market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the anal fistula market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the anal fistula market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of anal fistula across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of anal fistula by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of anal fistula by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with anal fistula across the seven major markets?
What is the size of the anal fistula patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of anal fistula?
What will be the growth rate of patients across the seven major markets?
Anal Fistula: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for anal fistula drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the anal fistula market?
What are the key regulatory events related to the anal fistula market?
What is the structure of clinical trial landscape by status related to the anal fistula market?
What is the structure of clinical trial landscape by phase related to the anal fistula market?
What is the structure of clinical trial landscape by route of administration related to the anal fistula market?
The anal fistula market has been comprehensively analyzed in IMARC's new report titled "Anal Fistula Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anal fistula is an abnormal tunnel or tract that forms between the anal canal or rectum and the skin surrounding the anus. It can vary in complexity, with some being straightforward and others more intricate with multiple tracts. The common symptoms associated with the ailment include persistent or recurrent pain around the anus, particularly during bowel movements, discharge of pus or blood from the opening near the anus, swelling or a lump near the anal region, itching or irritation around the anal area, and occasionally, fever. The specific indications experienced may vary depending on the characteristics of the fistula, and some patients may have minimal or no signs at all. Diagnosing an anal fistula typically involves a thorough examination by a healthcare professional, such as a colorectal surgeon. The diagnosis is made through a combination of physical exam and medical history review. The healthcare provider may visually inspect the anal area, looking for signs of an opening or discharge. Additional diagnostic tests, including endoanal ultrasound or magnetic resonance imaging (MRI), are also performed to visualize the fistula tract, determine its characteristics, and evaluate any underlying causes.
The escalating incidences of inflammation in the digestive tract that can weaken the tissues, impair healing, and create abnormal connections or tunnels between the anal canal or rectum and the surrounding skin, are primarily driving the anal fistula market. In addition to this, the rising cases of injuries or trauma to the anal or rectal area, such as during childbirth and surgery, infections in the perianal region, previous surgical procedures involving the anus or rectum, anal abscesses, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of fistula plugs made of biological or synthetic materials, since they offer a less invasive option with the potential for quicker healing and reduced recurrence rates, is further bolstering the market growth. Apart from this, the inflating application of intersphincteric fistula tract (LIFT) procedure that involves identifying and ligating the internal opening of the fistula and removing the diseased tissue is also acting as another significant growth-inducing factor. Additionally, the emerging popularity of minimally invasive techniques, such as video-assisted anal fistula treatment (VAAFT) and endoanal ultrasound-guided therapy (EUA), which allow for precise identification of the fistula tract and targeted intervention while minimizing tissue damage, is expected to drive the anal fistula market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the anal fistula market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for anal fistula and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anal fistula market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the anal fistula market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the anal fistula market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current anal fistula marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the anal fistula market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the anal fistula market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the anal fistula market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of anal fistula across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of anal fistula by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of anal fistula by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with anal fistula across the seven major markets?
What is the size of the anal fistula patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of anal fistula?
What will be the growth rate of patients across the seven major markets?
Anal Fistula: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for anal fistula drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the anal fistula market?
What are the key regulatory events related to the anal fistula market?
What is the structure of clinical trial landscape by status related to the anal fistula market?
What is the structure of clinical trial landscape by phase related to the anal fistula market?
What is the structure of clinical trial landscape by route of administration related to the anal fistula market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANAL FISTULA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ANAL FISTULA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANAL FISTULA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ANAL FISTULA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANAL FISTULA - UNMET NEEDS
10 ANAL FISTULA - KEY ENDPOINTS OF TREATMENT
11 ANAL FISTULA - MARKETED PRODUCTS
11.1 List of Anal Fistula Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ANAL FISTULA - PIPELINE DRUGS
12.1 List of Anal Fistula Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ANAL FISTULA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ANAL FISTULA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ANAL FISTULA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Anal Fistula - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Anal Fistula - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Anal Fistula - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Anal Fistula - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Anal Fistula - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Anal Fistula - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Anal Fistula - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Anal Fistula - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Anal Fistula - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Anal Fistula - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Anal Fistula - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Anal Fistula - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Anal Fistula - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Anal Fistula - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Anal Fistula - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Anal Fistula - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Anal Fistula - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Anal Fistula - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Anal Fistula - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Anal Fistula - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Anal Fistula - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Anal Fistula - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Anal Fistula - Access and Reimbursement Overview
16 ANAL FISTULA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ANAL FISTULA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ANAL FISTULA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANAL FISTULA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ANAL FISTULA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANAL FISTULA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 ANAL FISTULA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANAL FISTULA - UNMET NEEDS
10 ANAL FISTULA - KEY ENDPOINTS OF TREATMENT
11 ANAL FISTULA - MARKETED PRODUCTS
11.1 List of Anal Fistula Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 ANAL FISTULA - PIPELINE DRUGS
12.1 List of Anal Fistula Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. ANAL FISTULA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ANAL FISTULA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ANAL FISTULA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Anal Fistula - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Anal Fistula - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Anal Fistula - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Anal Fistula - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Anal Fistula - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Anal Fistula - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Anal Fistula - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Anal Fistula - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Anal Fistula - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Anal Fistula - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Anal Fistula - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Anal Fistula - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Anal Fistula - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Anal Fistula - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Anal Fistula - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Anal Fistula - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Anal Fistula - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Anal Fistula - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Anal Fistula - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Anal Fistula - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Anal Fistula - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Anal Fistula - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Anal Fistula - Access and Reimbursement Overview
16 ANAL FISTULA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ANAL FISTULA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ANAL FISTULA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
